

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1-8. (canceled).

9. **(currently amended):** A method for measuring an occupying ratio of a compound bound to the region consisting of the epitope determined by the antibodies 45531.111 and 45523.111 a strong binding site of CCR5 on a CCR5 expressing cell or a membrane fraction thereof, which comprises

(a) allowing a CCR5 expressing cell or a membrane fraction thereof to contact with a compound to be tested,

(b) allowing the test compound-bound cell or a membrane fraction thereof prepared in the above step (a) to contact with a labeled-anti-CCR5 antibody, wherein when an antagonist or agonist is bound to the strong binding site of CCR5, the antibody has a property of not binding to CCR 45531.111 or 45523.111 antibody, or an a labeled isotype control of the labeled anti-CCR5 45531.111 or 45523.111 antibody, and

(c) calculating an occupying ratio of the compound bound to the strong-binding site region consisting of the epitope determined by the antibodies 45531.111 and 45523.111 of CCR5 on the cell or membrane fraction thereof, based on the ratio of:

a bound amount of the anti-CCR5 45531.111 or 45523.111 antibody when the compound is bound to CCR5 corrected by using the labeled isotype control to

a bound amount of ~~the anti-CCR5-45531.111 or 45523.111 antibody~~ when the compound is not bound to CCR5 corrected by using the labeled isotype control, which is defined as 100%.

10-33. (canceled).

34. (new): The method according to claim 9, wherein the compound has IC50 values of 1.5 nmol/l to 4.2 nmol/l in the ligand binding inhibitory activity under 8 times washing condition.